Serveur d'exploration SRAS

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

How to reduce the likelihood of coronavirus-19 (CoV-19 or SARS-CoV-2) infection and lung inflammation mediated by IL-1.

Identifieur interne : 000586 ( 2020/Analysis ); précédent : 000585; suivant : 000587

How to reduce the likelihood of coronavirus-19 (CoV-19 or SARS-CoV-2) infection and lung inflammation mediated by IL-1.

Auteurs : P. Conti [Italie] ; C E Gallenga [Italie] ; G. Tetè [Italie] ; Al Caraffa [Italie] ; G. Ronconi [Italie] ; A. Younes [Italie] ; E. Toniato [Italie] ; R. Ross [États-Unis] ; S K Kritas [Grèce]

Source :

RBID : pubmed:32228825

Abstract

SARS-CoV-2, also referred to as CoV-19, is an RNA virus which can cause severe acute respiratory diseases (COVID-19), with serious infection of the lower respiratory tract followed by bronchitis, pneumonia and fibrosis. The severity of the disease depends on the efficiency of the immune system which, if it is weak, cannot stem the infection and its symptoms. The new CoV-19 spreads in the population at a rate of 0.8-3% more than normal flu and mostly affects men, since immune genes are more expressed on the X chromosome. If CoV-19 would spread with a higher incidence rate (over 10%), and affect the people who live in closed communities such as islands, it would cause many more deaths. Moreover, people from the poorest classes are most at risk because of lack of health care and should be given more assistance by the competent authorities. To avoid the aggravation of CoV-19 infection, and the collapse of the health system, individuals should remain at home in quarantine for a period of approximately one month in order to limit viral transmission. In the case of a pandemic, the severe shortage of respirators and protective clothing, due to the enormous demand and insufficient production, could lead the CoV-19 to kill a large number of individuals. At present, there is no drug capable of treating CoV-19 flu, the only therapeutic remedies are those aimed at the side effects caused by the virus, such as inflammation and pulmonary fibrosis, recognized as the first causes of death. One of the COVID-19 treatments involves inhaling a mixture of gaseous hydrogen and oxygen, obtaining better results than with oxygen alone. It was also noted that individuals vaccinated for viral and/or bacterial infectious diseases were less likely to become infected. In addition, germicidal UV radiation "breaks down" the oxygen O2 which then aggregate into O3 (ozone) molecules creating the ozone layer, capable of inhibiting viral replication and improving lung respiration. All these precautions should be taken into consideration to lower the risk of infection by CoV-19. New anti-viral therapies with new drugs should also be taken into consideration. For example, microbes are known to bind TLR, inducing IL-1, a pleiotropic cytokine, highly inflammatory, mediator of fever and fibrosis. Therefore, drugs that suppress IL-1 or IL-1R, also used for the treatment of rheumatoid arthritis are to be taken into consideration to treat COVID-19. We strongly believe that all these devices described above can lead to greater survival and. therefore, reduction in mortality in patients infected with CoV-19.

DOI: 10.23812/Editorial-Conti-2
PubMed: 32228825


Affiliations:


Links toward previous steps (curation, corpus...)


Links to Exploration step

pubmed:32228825

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">How to reduce the likelihood of coronavirus-19 (CoV-19 or SARS-CoV-2) infection and lung inflammation mediated by IL-1.</title>
<author>
<name sortKey="Conti, P" sort="Conti, P" uniqKey="Conti P" first="P" last="Conti">P. Conti</name>
<affiliation wicri:level="1">
<nlm:affiliation>Postgraduate Medical School, University of Chieti, Chieti, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Postgraduate Medical School, University of Chieti, Chieti</wicri:regionArea>
<wicri:noRegion>Chieti</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Gallenga, C E" sort="Gallenga, C E" uniqKey="Gallenga C" first="C E" last="Gallenga">C E Gallenga</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of Biomedical Sciences and Specialist Surgery, Section of Ophthalmology, University of Ferrara, Ferrara, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Biomedical Sciences and Specialist Surgery, Section of Ophthalmology, University of Ferrara, Ferrara</wicri:regionArea>
<wicri:noRegion>Ferrara</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Tete, G" sort="Tete, G" uniqKey="Tete G" first="G" last="Tetè">G. Tetè</name>
<affiliation wicri:level="3">
<nlm:affiliation>Specialization School in Oral Surgery, Vita-Salute San Raffaele University, Milan, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Specialization School in Oral Surgery, Vita-Salute San Raffaele University, Milan</wicri:regionArea>
<placeName>
<settlement type="city">Milan</settlement>
<region nuts="2">Lombardie</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Caraffa, Al" sort="Caraffa, Al" uniqKey="Caraffa A" first="Al" last="Caraffa">Al Caraffa</name>
<affiliation wicri:level="1">
<nlm:affiliation>School of Pharmacy, University of Camerino, Camerino, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>School of Pharmacy, University of Camerino, Camerino</wicri:regionArea>
<wicri:noRegion>Camerino</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Ronconi, G" sort="Ronconi, G" uniqKey="Ronconi G" first="G" last="Ronconi">G. Ronconi</name>
<affiliation wicri:level="3">
<nlm:affiliation>Clinica dei Pazienti del Territorio, Fondazione Policlinico Gemelli, Rome, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Clinica dei Pazienti del Territorio, Fondazione Policlinico Gemelli, Rome</wicri:regionArea>
<placeName>
<settlement type="city">Rome</settlement>
<region nuts="2">Latium</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Younes, A" sort="Younes, A" uniqKey="Younes A" first="A" last="Younes">A. Younes</name>
<affiliation wicri:level="1">
<nlm:affiliation>Medical Center "Mai più Dolore", Pescara, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Medical Center "Mai più Dolore", Pescara</wicri:regionArea>
<wicri:noRegion>Pescara</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Toniato, E" sort="Toniato, E" uniqKey="Toniato E" first="E" last="Toniato">E. Toniato</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of Medical, Oral and Biotechnological Sciences, University of Chieti, Chieti, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Medical, Oral and Biotechnological Sciences, University of Chieti, Chieti</wicri:regionArea>
<wicri:noRegion>Chieti</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Ross, R" sort="Ross, R" uniqKey="Ross R" first="R" last="Ross">R. Ross</name>
<affiliation wicri:level="2">
<nlm:affiliation>University of Pennsylvania School of Veterinary Medicine, Philadelphia, PA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of Pennsylvania School of Veterinary Medicine, Philadelphia, PA</wicri:regionArea>
<placeName>
<region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Kritas, S K" sort="Kritas, S K" uniqKey="Kritas S" first="S K" last="Kritas">S K Kritas</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of Microbiology and Infectious Diseases, School of Veterinary Medicine, Aristotle University of Thessaloniki, Macedonia, Greece.</nlm:affiliation>
<country xml:lang="fr">Grèce</country>
<wicri:regionArea>Department of Microbiology and Infectious Diseases, School of Veterinary Medicine, Aristotle University of Thessaloniki, Macedonia</wicri:regionArea>
<wicri:noRegion>Macedonia</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32228825</idno>
<idno type="pmid">32228825</idno>
<idno type="doi">10.23812/Editorial-Conti-2</idno>
<idno type="wicri:Area/PubMed/Corpus">000447</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000447</idno>
<idno type="wicri:Area/PubMed/Curation">000447</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000447</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000466</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000466</idno>
<idno type="wicri:Area/Ncbi/Merge">003643</idno>
<idno type="wicri:Area/Ncbi/Curation">003643</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">003643</idno>
<idno type="wicri:doubleKey">0393-974X:2020:Conti P:how:to:reduce</idno>
<idno type="wicri:Area/Main/Merge">000586</idno>
<idno type="wicri:Area/Main/Curation">000586</idno>
<idno type="wicri:Area/Main/Exploration">000586</idno>
<idno type="wicri:Area/2020/Extraction">000586</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">How to reduce the likelihood of coronavirus-19 (CoV-19 or SARS-CoV-2) infection and lung inflammation mediated by IL-1.</title>
<author>
<name sortKey="Conti, P" sort="Conti, P" uniqKey="Conti P" first="P" last="Conti">P. Conti</name>
<affiliation wicri:level="1">
<nlm:affiliation>Postgraduate Medical School, University of Chieti, Chieti, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Postgraduate Medical School, University of Chieti, Chieti</wicri:regionArea>
<wicri:noRegion>Chieti</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Gallenga, C E" sort="Gallenga, C E" uniqKey="Gallenga C" first="C E" last="Gallenga">C E Gallenga</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of Biomedical Sciences and Specialist Surgery, Section of Ophthalmology, University of Ferrara, Ferrara, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Biomedical Sciences and Specialist Surgery, Section of Ophthalmology, University of Ferrara, Ferrara</wicri:regionArea>
<wicri:noRegion>Ferrara</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Tete, G" sort="Tete, G" uniqKey="Tete G" first="G" last="Tetè">G. Tetè</name>
<affiliation wicri:level="3">
<nlm:affiliation>Specialization School in Oral Surgery, Vita-Salute San Raffaele University, Milan, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Specialization School in Oral Surgery, Vita-Salute San Raffaele University, Milan</wicri:regionArea>
<placeName>
<settlement type="city">Milan</settlement>
<region nuts="2">Lombardie</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Caraffa, Al" sort="Caraffa, Al" uniqKey="Caraffa A" first="Al" last="Caraffa">Al Caraffa</name>
<affiliation wicri:level="1">
<nlm:affiliation>School of Pharmacy, University of Camerino, Camerino, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>School of Pharmacy, University of Camerino, Camerino</wicri:regionArea>
<wicri:noRegion>Camerino</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Ronconi, G" sort="Ronconi, G" uniqKey="Ronconi G" first="G" last="Ronconi">G. Ronconi</name>
<affiliation wicri:level="3">
<nlm:affiliation>Clinica dei Pazienti del Territorio, Fondazione Policlinico Gemelli, Rome, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Clinica dei Pazienti del Territorio, Fondazione Policlinico Gemelli, Rome</wicri:regionArea>
<placeName>
<settlement type="city">Rome</settlement>
<region nuts="2">Latium</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Younes, A" sort="Younes, A" uniqKey="Younes A" first="A" last="Younes">A. Younes</name>
<affiliation wicri:level="1">
<nlm:affiliation>Medical Center "Mai più Dolore", Pescara, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Medical Center "Mai più Dolore", Pescara</wicri:regionArea>
<wicri:noRegion>Pescara</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Toniato, E" sort="Toniato, E" uniqKey="Toniato E" first="E" last="Toniato">E. Toniato</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of Medical, Oral and Biotechnological Sciences, University of Chieti, Chieti, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Medical, Oral and Biotechnological Sciences, University of Chieti, Chieti</wicri:regionArea>
<wicri:noRegion>Chieti</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Ross, R" sort="Ross, R" uniqKey="Ross R" first="R" last="Ross">R. Ross</name>
<affiliation wicri:level="2">
<nlm:affiliation>University of Pennsylvania School of Veterinary Medicine, Philadelphia, PA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of Pennsylvania School of Veterinary Medicine, Philadelphia, PA</wicri:regionArea>
<placeName>
<region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Kritas, S K" sort="Kritas, S K" uniqKey="Kritas S" first="S K" last="Kritas">S K Kritas</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of Microbiology and Infectious Diseases, School of Veterinary Medicine, Aristotle University of Thessaloniki, Macedonia, Greece.</nlm:affiliation>
<country xml:lang="fr">Grèce</country>
<wicri:regionArea>Department of Microbiology and Infectious Diseases, School of Veterinary Medicine, Aristotle University of Thessaloniki, Macedonia</wicri:regionArea>
<wicri:noRegion>Macedonia</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series>
<title level="j">Journal of biological regulators and homeostatic agents</title>
<idno type="ISSN">0393-974X</idno>
<imprint>
<date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass></textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">SARS-CoV-2, also referred to as CoV-19, is an RNA virus which can cause severe acute respiratory diseases (COVID-19), with serious infection of the lower respiratory tract followed by bronchitis, pneumonia and fibrosis. The severity of the disease depends on the efficiency of the immune system which, if it is weak, cannot stem the infection and its symptoms. The new CoV-19 spreads in the population at a rate of 0.8-3% more than normal flu and mostly affects men, since immune genes are more expressed on the X chromosome. If CoV-19 would spread with a higher incidence rate (over 10%), and affect the people who live in closed communities such as islands, it would cause many more deaths. Moreover, people from the poorest classes are most at risk because of lack of health care and should be given more assistance by the competent authorities. To avoid the aggravation of CoV-19 infection, and the collapse of the health system, individuals should remain at home in quarantine for a period of approximately one month in order to limit viral transmission. In the case of a pandemic, the severe shortage of respirators and protective clothing, due to the enormous demand and insufficient production, could lead the CoV-19 to kill a large number of individuals. At present, there is no drug capable of treating CoV-19 flu, the only therapeutic remedies are those aimed at the side effects caused by the virus, such as inflammation and pulmonary fibrosis, recognized as the first causes of death. One of the COVID-19 treatments involves inhaling a mixture of gaseous hydrogen and oxygen, obtaining better results than with oxygen alone. It was also noted that individuals vaccinated for viral and/or bacterial infectious diseases were less likely to become infected. In addition, germicidal UV radiation "breaks down" the oxygen O2 which then aggregate into O3 (ozone) molecules creating the ozone layer, capable of inhibiting viral replication and improving lung respiration. All these precautions should be taken into consideration to lower the risk of infection by CoV-19. New anti-viral therapies with new drugs should also be taken into consideration. For example, microbes are known to bind TLR, inducing IL-1, a pleiotropic cytokine, highly inflammatory, mediator of fever and fibrosis. Therefore, drugs that suppress IL-1 or IL-1R, also used for the treatment of rheumatoid arthritis are to be taken into consideration to treat COVID-19. We strongly believe that all these devices described above can lead to greater survival and. therefore, reduction in mortality in patients infected with CoV-19.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>Grèce</li>
<li>Italie</li>
<li>États-Unis</li>
</country>
<region>
<li>Latium</li>
<li>Lombardie</li>
<li>Pennsylvanie</li>
</region>
<settlement>
<li>Milan</li>
<li>Rome</li>
</settlement>
</list>
<tree>
<country name="Italie">
<noRegion>
<name sortKey="Conti, P" sort="Conti, P" uniqKey="Conti P" first="P" last="Conti">P. Conti</name>
</noRegion>
<name sortKey="Caraffa, Al" sort="Caraffa, Al" uniqKey="Caraffa A" first="Al" last="Caraffa">Al Caraffa</name>
<name sortKey="Gallenga, C E" sort="Gallenga, C E" uniqKey="Gallenga C" first="C E" last="Gallenga">C E Gallenga</name>
<name sortKey="Ronconi, G" sort="Ronconi, G" uniqKey="Ronconi G" first="G" last="Ronconi">G. Ronconi</name>
<name sortKey="Tete, G" sort="Tete, G" uniqKey="Tete G" first="G" last="Tetè">G. Tetè</name>
<name sortKey="Toniato, E" sort="Toniato, E" uniqKey="Toniato E" first="E" last="Toniato">E. Toniato</name>
<name sortKey="Younes, A" sort="Younes, A" uniqKey="Younes A" first="A" last="Younes">A. Younes</name>
</country>
<country name="États-Unis">
<region name="Pennsylvanie">
<name sortKey="Ross, R" sort="Ross, R" uniqKey="Ross R" first="R" last="Ross">R. Ross</name>
</region>
</country>
<country name="Grèce">
<noRegion>
<name sortKey="Kritas, S K" sort="Kritas, S K" uniqKey="Kritas S" first="S K" last="Kritas">S K Kritas</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/2020/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000586 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/2020/Analysis/biblio.hfd -nk 000586 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    2020
   |étape=   Analysis
   |type=    RBID
   |clé=     pubmed:32228825
   |texte=   How to reduce the likelihood of coronavirus-19 (CoV-19 or SARS-CoV-2) infection and lung inflammation mediated by IL-1.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/2020/Analysis/RBID.i   -Sk "pubmed:32228825" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/2020/Analysis/biblio.hfd   \
       | NlmPubMed2Wicri -a SrasV1 

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021